GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Grace Therapeutics Inc (NAS:GRCE) » Definitions » Book Value per Share

GRCE (Grace Therapeutics) Book Value per Share : $5.54 (As of Sep. 2024)


View and export this data going back to 2011. Start your Free Trial

What is Grace Therapeutics Book Value per Share?

Grace Therapeutics's book value per share for the quarter that ended in Sep. 2024 was $5.54.

During the past 12 months, Grace Therapeutics's average Book Value Per Share Growth Rate was -22.00% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -20.00% per year. During the past 5 years, the average Book Value Per Share Growth Rate was 2.30% per year. During the past 10 years, the average Book Value Per Share Growth Rate was -25.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Grace Therapeutics was 166.50% per year. The lowest was -61.60% per year. And the median was 2.50% per year.

Grace Therapeutics's current price is $3.58. Its book value per share for the quarter that ended in Sep. 2024 was $5.54. Hence, today's PB Ratio of Grace Therapeutics is 0.65.

During the past 13 years, the highest P/B Ratio of Grace Therapeutics was 6.25. The lowest was 0.12. And the median was 0.68.


Grace Therapeutics Book Value per Share Historical Data

The historical data trend for Grace Therapeutics's Book Value per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Grace Therapeutics Book Value per Share Chart

Grace Therapeutics Annual Data
Trend Feb14 Feb15 Feb16 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Book Value per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.91 12.82 14.67 9.14 6.57

Grace Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Book Value per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.10 6.88 6.57 5.85 5.54

Competitive Comparison of Grace Therapeutics's Book Value per Share

For the Biotechnology subindustry, Grace Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Grace Therapeutics's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Grace Therapeutics's PB Ratio distribution charts can be found below:

* The bar in red indicates where Grace Therapeutics's PB Ratio falls into.



Grace Therapeutics Book Value per Share Calculation

Grace Therapeutics's Book Value Per Share for the fiscal year that ended in Mar. 2024 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(61.74-0.00)/9.40
=6.57

Grace Therapeutics's Book Value Per Share for the quarter that ended in Sep. 2024 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(56.13-0.00)/10.14
=5.54

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theoretically it is what the shareholders will receive if the company is liquidated. Total Stockholders Equity is a balance sheet item and equal to Total Assets less Total Liabilities of the company.

Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.


Grace Therapeutics  (NAS:GRCE) Book Value per Share Explanation

Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.

For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.


Grace Therapeutics Book Value per Share Related Terms

Thank you for viewing the detailed overview of Grace Therapeutics's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Grace Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
103 Carnegie Center, Suite 300, Princeton, NJ, USA, 08540
Grace Therapeutics Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. The company's lead drug candidate, GTx-104, is a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage.
Executives
George Kottayil director 49 OLD BEAR BROOK ROAD, PRINCETON NJ 08540
A Brian Davis director C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380
Edward Neugeboren director 282 NEW NORWALK ROAD, NEW CANAAN CT 06840
Vimal Kavuru director 11 MAACKA DRIVE, HOLMDEL NJ 07733
Donald Olds director 545 PROMENADE DU CENTROPOLIS, SUITE 100, LAVAL A8 H7T 0A3
Amresh Kumar officer: VP Program Management 3009, BOUL. DE LA CONCORDE EAST, SUITE 102, LAVAL A8 H7E 2B5
Carrie D'andrea officer: VP Clinical Operations 3009, BOUL. DE LA CONCORDE EAST, SUITE 102, LAVAL A8 H7E 2B5
Prashant Kohli officer: Chief Executive Officer 206 CAMBRIDGE LANE, NEWTOWN PA 13940
R. Loch Macdonald officer: Chief Medical Officer 200 CONNELL DRIVE, SUITE 1600, BERKELEY HEIGHTS NJ 07922
Michael Derby director 303 SOUTH BROADWAY, SUITE 125, TARRYTOWN NY 10591
William A Haseltine director
Rajitha Grace 2018 Irrevocable Trust 10 percent owner 40 BEY LEA ROAD, SUITE C 202, TOMS RIVER NJ 08753
Swami Sambamurty Iyer 10 percent owner 20 TULSA COURT, MONMOUTH JUNCTION NJ 08852
Brian D. Ford officer: CHIEF FINANCIAL OFFICER 3009, BOUL. DE LA CONCORDE EAST, SUITE 102, LAVAL A8 H7E 2B5
John Canan director C/O REV GROUP, INC., 111 EAST KILBOURN AVENUE, SUITE 2600, MILWAUKEE WI 53202